These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 24150779)

  • 1. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.
    Kappos L; Gold R; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Sarda SP; Agarwal S; Zhang A; Sheikh SI; Seidman E; Dawson KT
    Mult Scler; 2014 Feb; 20(2):243-52. PubMed ID: 24150779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
    Kita M; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Sarda SP; Agarwal S; Kong J; Zhang A; Viglietta V; Sheikh SI; Seidman E; Dawson KT
    Mult Scler; 2014 Feb; 20(2):253-7. PubMed ID: 24150778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
    Havrdova E; Hutchinson M; Kurukulasuriya NC; Raghupathi K; Sweetser MT; Dawson KT; Gold R
    Expert Opin Pharmacother; 2013 Oct; 14(15):2145-56. PubMed ID: 23971970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
    Matolcsi J; Rózsa C
    Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
    Fox RJ; Kita M; Cohan SL; Henson LJ; Zambrano J; Scannevin RH; O'Gorman J; Novas M; Dawson KT; Phillips JT
    Curr Med Res Opin; 2014 Feb; 30(2):251-62. PubMed ID: 24131282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
    Bar-Or A; Gold R; Kappos L; Arnold DL; Giovannoni G; Selmaj K; O'Gorman J; Stephan M; Dawson KT
    J Neurol; 2013 Sep; 260(9):2297-305. PubMed ID: 23797999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fumaric acid ester BG-12: a new option in MS therapy.
    Lee DH; Stangel M; Gold R; Linker RA
    Expert Rev Neurother; 2013 Aug; 13(8):951-8. PubMed ID: 23944289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Burness CB; Deeks ED
    CNS Drugs; 2014 Apr; 28(4):373-87. PubMed ID: 24623127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Blair HA
    Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
    Hutchinson M; Fox RJ; Miller DH; Phillips JT; Kita M; Havrdova E; O'Gorman J; Zhang R; Novas M; Viglietta V; Dawson KT
    J Neurol; 2013 Sep; 260(9):2286-96. PubMed ID: 23749293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Deeks ED
    Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
    Kappos L; Giovannoni G; Gold R; Phillips JT; Arnold DL; Hotermans C; Zhang A; Viglietta V; Fox RJ;
    Eur J Neurol; 2015 Apr; 22(4):664-71. PubMed ID: 25557371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl fumarate for relapsing-remitting multiple sclerosis.
    Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.